

Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028

Market Report | 2023-10-25 | 216 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global cardiac marker testing market is projected to reach USD 6.9 billion by 2028 from USD 4.1 billion in 2022, growing at a CAGR of 9.4% during the forecast period. The projected surge in market growth for cardiac marker testing is underpinned by a confluence of compelling advantages. Notably, cardiac marker testing is driven by aging population, rising cases of cardiovascular diseases, increase in research & funding initiatives from public/private organizations to discover novel cardiac biomarkers. Furthermore, the escalating early detection of heart failure diseases with improved efficacy for diagnosing heart conditions amplifies the demand for advanced treatment modalities, with cardiac marker testing positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of cardiac marker testing adoption in the forthcoming forecasting years.

"Troponin I and T segment to register largest market share in 2022-2028"

Based on the biomarker type, cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Brain Natriuretic Peptide (BNP and NT-PROBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment register a largest market share over the forecast period of 2022-2028. The growth of this segment is propelled by factors such as exceptional sensitivity and specificity, prolonged elevation duration (with levels rising over 4-8 hours, peaking at 10-24 hours, and declining over ten days), and the swift prediction of outcomes. Moreover, lab technicians are more adept at utilizing these markers in comparison to other biomarkers, further fueling the segment's advancement.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"Laboratory testing facilities segment held the largest share of cardiac marker testing market in 2022, by End-user."

Based on the end-user, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2022, the laboratory testing facilities segment accounted for the largest share of 61.2% of the global cardiac marker testing market. The growth of this segment is being propelled by factors including increased testing efficiency, superior sensitivity and diagnostic precision in comparison to point-of-care testing, and a strong preference for laboratory testing over point-of-care testing.

"Asia Pacific to register significant growth rate in the market during the forecast period."

For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for cardiac marker testing. There are several drivers that contributed to this growth:

The Asia Pacific market is experiencing growth due to increased investments by government agencies in emerging countries, aimed at enhancing healthcare infrastructure. Additionally, the market is benefiting from the rise in independent clinical laboratories, a substantial patient population, and strategic initiatives by industry players to expand their offerings of cardiac testing products in the Asia Pacific region.

A breakdown of the primary participants referred to for this report is provided below:

-□By Company Type: Tier 1-43%, Tier 2-30%, and Tier 3- 27%

-□By Designation: C-level-10%, Director-level-15%, and Others-75%

-□By Region: North America-40%, Europe-30%, Asia Pacific-23%, Latin America-5%, and the Middle East & Africa-2%

Prominent players in this market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), , Thermo Fisher Scientific Inc. (US) among others.

Research Coverage

-□The report studies the marker testing market based on products, biomarker type, diseases, end user, and region.

-□The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.

-□The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.

-□The report studies micro markets with respect to their growth trends, prospects, and contributions to the global cardiac marker testing market

-□The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the new entrants/ market leaders/smaller firms in this market with investment evaluation viability within the cardiac marker testing market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, challenges, growth catalysts and prospects, thereby empowering strategic decision-making with astute discernment.

The report provides insights on the following pointers:

-□Analysis of key drivers (increasing prevalence of cardiovascular diseases, Increasing geriatric population and subsequent rise in heart conditions worldwide, Ongoing clinical trials for the identification of novel cardiac biomarkers), restraints (Technical issues

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

related to sample collection & storage, Unfavorable regulatory processes and limited reimbursement structure), opportunities (Point-of-care testing (POCT) with cardiac biomarkers, Emerging markets offers high-growth opportunities, Ongoing research on novel cardiac biomarkers for cardiovascular diseases), and challenges (Challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market

-□Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cardiac marker testing market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the cardiac marker testing market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), among others.

Table of Contents:

1	INTRODUCTION	28	
1.1	STUDY OBJECTIVES	28	
1.2	MARKET DEFINITION	28	
1.2.1	INCLUSIONS AND EXCLUSIONS OF STUDY	29	
1.3	MARKET SCOPE	29	
1.3.1	MARKETS COVERED	29	
1.3.2	REGIONS COVERED	30	
1.4	YEARS CONSIDERED	30	
1.5	CURRENCY	31	
1.6	RESEARCH LIMITATIONS	31	
1.7	MARKET STAKEHOLDERS	31	
1.8	SUMMARY OF CHANGES	31	
1.8.1	RECESSION IMPACT	32	
2	RESEARCH METHODOLOGY	33	
2.1	RESEARCH DATA	33	
2.2	RESEARCH DESIGN	34	
2.2.1	SECONDARY RESEARCH	34	
FIGURE 1		KEY DATA FROM SECONDARY SOURCES	36
2.2.2	PRIMARY RESEARCH	36	
2.2.2.1	Primary sources	37	
2.2.2.2	Key industry insights	38	
2.2.2.3	Breakdown of primaries	38	
FIGURE 2		BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	38
FIGURE 3		BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	39
2.3	MARKET SIZE ESTIMATION	39	
FIGURE 4		RESEARCH METHODOLOGY: HYPOTHESIS BUILDING	40
2.3.1	BOTTOM-UP APPROACH	41	
2.3.2	APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH	41	
FIGURE 5		CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)	41
2.3.3	APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION	42	
FIGURE 6		CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH	42
2.3.4	APPROACH 3: TOP-DOWN APPROACH	43	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.3.5	APPROACH 4: PRIMARY INTERVIEWS	43
FIGURE 7	CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: TOP-DOWN APPROACH	43
2.4	DATA TRIANGULATION AND MARKET BREAKDOWN	44
FIGURE 8	DATA TRIANGULATION METHODOLOGY	45
2.5	MARKET SHARE ASSESSMENT	46
2.6	STUDY ASSUMPTIONS	46
2.7	RISK ASSESSMENT	46
TABLE 1	LIMITATIONS AND ASSOCIATED RISKS	46
2.8	GROWTH RATE ASSUMPTIONS	47
2.9	RECESSION IMPACT	47
3	EXECUTIVE SUMMARY	48
FIGURE 9	CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2023 VS. 2028 (USD MILLION)	48
FIGURE 10	CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	49
FIGURE 11	CARDIAC MARKER TESTING MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)	49
FIGURE 12	CARDIAC MARKER TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	50
FIGURE 13	GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET	51
4	PREMIUM INSIGHTS	52
4.1	CARDIAC MARKER TESTING MARKET OVERVIEW	52
FIGURE 14	RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET	52
4.2	NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY AND END USER, 2022	53
FIGURE 15	LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022	53
4.3	CARDIAC MARKER TESTING MARKET: REGIONAL MIX	54
FIGURE 16	NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD	54
4.4	CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	55
FIGURE 17	CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD	55
5	MARKET OVERVIEW	56
5.1	INTRODUCTION	56
FIGURE 18	CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	56
5.1.1	DRIVERS	57
5.1.1.1	Rising prevalence of cardiovascular diseases	57
5.1.1.2	Increasing geriatric population and subsequent rise in heart conditions worldwide	57
5.1.1.3	Growing research and funding initiatives from public and private organizations	58
5.1.1.4	Rising clinical studies for identification of novel cardiac biomarkers	58
5.1.2	RESTRAINTS	58
5.1.2.1	Technical issues related to sample collection and storage	58
5.1.2.2	Unfavorable regulatory processes and limited reimbursement structure	59
5.1.3	OPPORTUNITIES	60
5.1.3.1	Point-of-care testing with cardiac biomarkers	60
5.1.3.2	Ongoing research on novel cardiac biomarkers for cardiovascular diseases	60
5.1.3.3	Emerging markets	61
5.1.4	CHALLENGES	61
5.1.4.1	Challenges associated with biomarker assay validation	61
5.2	KEY STAKEHOLDERS AND BUYING CRITERIA	62
5.2.1	KEY STAKEHOLDERS IN BUYING PROCESS	62
FIGURE 19	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING MARKET	62
TABLE 2	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%)	62

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.3	PORTER'S FIVE FORCES ANALYSIS	62	
	TABLE 3	CARDIAC MARKER TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS	63
5.3.1	THREAT OF NEW ENTRANTS	63	
5.3.2	THREAT OF SUBSTITUTES	63	
5.3.3	BARGAINING POWER OF SUPPLIERS	63	
5.3.4	BARGAINING POWER OF BUYERS	63	
5.3.5	INTENSITY OF COMPETITIVE RIVALRY	64	
5.4	REGULATORY ANALYSIS	64	
5.4.1	US	64	
	TABLE 4	US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS	65
5.4.2	EUROPE	65	
	TABLE 5	EUROPE: CLASSIFICATION OF IVD DEVICES	65
5.4.3	JAPAN	66	
	TABLE 6	JAPAN: CLASSIFICATION OF IVD REAGENTS	66
	TABLE 7	JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	66
5.5	REIMBURSEMENT SCENARIO	66	
	TABLE 8	REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS	67
5.6	ECOSYSTEM MAPPING	68	
5.7	VALUE CHAIN ANALYSIS	68	
5.7.1	RESEARCH & DEVELOPMENT	68	
5.7.2	PROCUREMENT AND PRODUCT DEVELOPMENT	68	
5.7.3	MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES	68	
	FIGURE 20	VALUE CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET	69
5.8	SUPPLY CHAIN ANALYSIS	69	
5.8.1	PROMINENT COMPANIES	69	
5.8.2	SMALL & MEDIUM-SIZED COMPANIES	69	
5.8.3	END USERS	69	
	FIGURE 21	SUPPLY CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET	70
5.9	PRICING ANALYSIS	70	
	TABLE 9	AVERAGE SELLING PRICE OF CARDIAC BIOMARKER TROPONIN I AND T TEST KITS, 2021	70
	TABLE 10	AVERAGE SELLING PRICE OF CARDIAC BIOMARKER BPN AND NT-PROBNP TEST KITS, 2021	71
	TABLE 11	AVERAGE SELLING PRICE OF CARDIAC BIOMARKER MYOGLOBIN TEST KITS, 2021	71
	TABLE 12	AVERAGE SELLING PRICE OF CARDIAC BIOMARKER CK-MB TEST KITS, 2022	71
	TABLE 13	AVERAGE SELLING PRICE OF CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS, 2022	71
	TABLE 14	AVERAGE SELLING PRICE TREND OF CARDIAC MARKER TEST KITS, BY COUNTRY, 2021-2023 (USD)	72
5.10	PATENT ANALYSIS	72	
	FIGURE 22	TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING, JANUARY 2012-SEPTEMBER 2022	73
	FIGURE 23	TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING, JANUARY 2012-SEPTEMBER 2022	73
5.11	TRADE ANALYSIS	73	
	TABLE 15	IMPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018-2022 (USD THOUSAND)	74
	TABLE 16	EXPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018-2022 (USD THOUSAND)	74
5.12	CASE STUDIES	75	
	TABLE 17	CASE STUDY: BREAKTHROUGH IN ACUTE MYOCARDIAL INFARCTION DIAGNOSIS WITH HIGH-SENSITIVITY TROPONIN I ASSAYS	75
5.13	KEY CONFERENCES AND EVENTS, 2023-2024	75	
	TABLE 18	CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023-2024	75
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS	76	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 24 □ EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX □ 76

5.15 □ IMPACT OF RECESSION ON CARDIAC MARKER TESTING MARKET □ 76

6 □ CARDIAC MARKER TESTING MARKET, BY PRODUCT □ 78

6.1 □ INTRODUCTION □ 79

TABLE 19 □ CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) □ 79

6.2 □ REAGENTS & KITS □ 79

6.2.1 □ RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND □ 79

TABLE 20 □ CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) □ 80

TABLE 21 □ CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 80

6.3 □ INSTRUMENTS □ 81

TABLE 22 □ CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) □ 81

TABLE 23 □ CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) □ 81

TABLE 24 □ CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 82

6.3.1 □ CHEMILUMINESCENCE □ 82

6.3.1.1 □ Most preferred method for quantifying cardiac biomarkers □ 82

TABLE 25 □ CHEMILUMINESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) □ 83

TABLE 26 □ CHEMILUMINESCENCE INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 83

6.3.2 □ IMMUNOFLUORESCENCE □ 84

6.3.2.1 □ Demand for stable and safer reagents to support market growth □ 84

TABLE 27 □ IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) □ 84

TABLE 28 □ IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 85

6.3.3 □ ELISA □ 85

6.3.3.1 □ Long shelf life and ease of use to propel growth □ 85

TABLE 29 □ ELISA INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) □ 85

TABLE 30 □ ELISA INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 86

6.3.4 □ IMMUNOCHROMATOGRAPHY □ 86

6.3.4.1 □ Increasing use in point-of-care settings to propel adoption □ 86

TABLE 31 □ IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) □ 87

TABLE 32 □ IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 87

7 □ CARDIAC MARKER TESTING MARKET, BY INDICATION □ 88

7.1 □ INTRODUCTION □ 89

TABLE 33 □ CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021-2028 (USD MILLION) □ 89

7.2 □ MYOCARDIAL INFARCTION □ 89

7.2.1 □ AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION TO DRIVE MARKET □ 89

TABLE 34 □ CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2021-2028 (USD MILLION) □ 90

7.3 □ CONGESTIVE HEART FAILURE □ 90

7.3.1 □ INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH □ 90

TABLE 35 □ CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2021-2028 (USD MILLION) □ 91

7.4 □ ACUTE CORONARY SYNDROME □ 91

7.4.1 □ INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS □ 91

TABLE 36 □ CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2021-2028 (USD MILLION) □ 92

7.5 □ ATHEROSCLEROSIS □ 92

7.5.1 □ HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET □ 92

TABLE 37 □ CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2021-2028 (USD MILLION) □ 93

7.6 □ ISCHEMIA □ 93

7.6.1 □ INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS □ 93

TABLE 38 □ CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2021-2028 (USD MILLION) □ 94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 95

8.1 INTRODUCTION 96

TABLE 39 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) 96

8.2 TROPONIN I AND T 96

8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 96

TABLE 40 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021-2028 (USD MILLION) 97

TABLE 41 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION) 97

TABLE 42 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY REGION, 2021-2028 (USD MILLION) 98

8.3 CREATINE KINASE-MB 98

8.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH 98

TABLE 43 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021-2028 (USD MILLION) 99

TABLE 44 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION) 99

TABLE 45 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY REGION, 2021-2028 (USD MILLION) 100

8.4 BRAIN NATRIURETIC PEPTIDE 100

8.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 100

TABLE 46 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY INDICATION, 2021-2028 (USD MILLION) 101

TABLE 47 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2021-2028 (USD MILLION) 101

TABLE 48 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2021-2028 (USD MILLION) 102

8.5 MYOGLOBIN 102

8.5.1 USED TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS 102

TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY INDICATION, 2021-2028 (USD MILLION) 102

TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2021-2028 (USD MILLION) 103

TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2021-2028 (USD MILLION) 103

8.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN 103

8.6.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION 103

TABLE 52 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY INDICATION, 2021-2028 (USD MILLION) 104

TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY END USER, 2021-2028 (USD MILLION) 104

TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY REGION, 2021-2028 (USD MILLION) 105

8.7 OTHER CARDIAC BIOMARKERS 105

TABLE 55 OTHER CARDIAC BIOMARKERS MARKET, BY INDICATION, 2021-2028 (USD MILLION) 106

TABLE 56 OTHER CARDIAC BIOMARKERS MARKET, BY END USER, 2021-2028 (USD MILLION) 106

TABLE 57 OTHER CARDIAC BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION) 107

9 CARDIAC MARKER TESTING MARKET, BY END USER 108

9.1 INTRODUCTION 109

TABLE 58 CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION) 109

9.2 LABORATORY TESTING FACILITIES 109

TABLE 59 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2021-2028 (USD MILLION) 110

TABLE 60 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2021-2028 (USD MILLION) 110

9.2.1 HOSPITAL LABORATORIES 110

9.2.1.1 Early diagnosis associated with in-house labs to support market growth 110

TABLE 61 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION) 111

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.2.2 REFERENCE LABORATORIES 111

9.2.2.1 Affordable and time-efficient services associated with reference laboratories to drive market 111

TABLE 62 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021-2028 (USD MILLION) 112

9.2.3 CONTRACT TESTING LABORATORIES 112

9.2.3.1 Ability to perform multiple tests to propel market 112

TABLE 63 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2021-2028 (USD MILLION) 112

9.3 ACADEMIC INSTITUTES 113

9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 113

TABLE 64 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 113

9.4 POINT-OF-CARE TESTING FACILITIES 113

9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO PROPEL MARKET 113

TABLE 65 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2021-2028 (USD MILLION) 114

10 CARDIAC MARKER TESTING MARKET, BY REGION 115

10.1 INTRODUCTION 116

TABLE 66 CARDIAC MARKER TESTING MARKET, BY REGION, 2021-2028 (USD MILLION) 116

10.2 NORTH AMERICA 117

10.2.1 NORTH AMERICA: RECESSION IMPACT 117

FIGURE 25 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 117

TABLE 67 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 118

TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 118

TABLE 69 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 118

TABLE 70 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) 119

TABLE 71 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION) 119

10.2.2 US 120

10.2.2.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 120

TABLE 72 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 120

10.2.3 CANADA 120

10.2.3.1 Government initiatives to support market growth 120

TABLE 73 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 121

10.3 EUROPE 121

10.3.1 EUROPE: RECESSION IMPACT 121

TABLE 74 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 122

TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 122

TABLE 76 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 122

TABLE 77 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) 123

TABLE 78 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION) 123

10.3.2 GERMANY 123

10.3.2.1 Favorable government policies to support market growth 123

TABLE 79 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 124

10.3.3 FRANCE 124

10.3.3.1 Rising geriatric population to drive market 124

TABLE 80 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 124

10.3.4 UK 125

10.3.4.1 Government initiatives to boost adoption of cardiac biomarkers 125

TABLE 81 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 125

10.3.5 ITALY 125

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.3.5.1 Adoption of advanced diagnostic technologies to drive market 125

TABLE 82 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 126

10.3.6 SPAIN 126

10.3.6.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing 126

TABLE 83 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 126

10.3.7 REST OF EUROPE 126

TABLE 84 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 127

10.4 ASIA PACIFIC 127

10.4.1 ASIA PACIFIC: RECESSION IMPACT 127

FIGURE 26 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 128

TABLE 85 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 129

TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 129

TABLE 87 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 130

TABLE 88 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) 130

TABLE 89 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION) 131

10.4.2 JAPAN 131

10.4.2.1 Presence of advanced laboratory facilities to drive market 131

TABLE 90 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 131

10.4.3 CHINA 132

10.4.3.1 Growing number of independent clinical laboratories to drive demand for cardiac markers 132

TABLE 91 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 132

10.4.4 INDIA 132

10.4.4.1 Presence of large patient population to drive demand 132

TABLE 92 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 133

10.4.5 AUSTRALIA 133

10.4.5.1 Increasing healthcare expenditure to support market growth 133

TABLE 93 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 133

10.4.6 SOUTH KOREA 134

10.4.6.1 Growing number of private hospitals to drive adoption of advanced testing services 134

TABLE 94 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 134

10.4.7 REST OF ASIA PACIFIC 134

TABLE 95 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 134

10.5 LATIN AMERICA 135

10.5.1 LATIN AMERICA: RECESSION IMPACT 135

TABLE 96 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 135

TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 136

TABLE 98 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION) 136

TABLE 99 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION) 137

TABLE 100 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION) 137

10.5.2 BRAZIL 137

10.5.2.1 Increasing government support for advancements in healthcare to support market growth 137

TABLE 101 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 138

10.5.3 MEXICO 138

10.5.3.1 Rising demand for technologically advanced products to drive uptake of cardiac markers 138

TABLE 102 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 138

10.5.4 REST OF LATIN AMERICA 139

TABLE 103 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 139

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.6	MIDDLE EAST & AFRICA	139
10.6.1	IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS	139
10.6.2	MIDDLE EAST & AFRICA: RECESSION IMPACT	139
TABLE 104	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	140
TABLE 105	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)	140
TABLE 106	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021-2028 (USD MILLION)	141
TABLE 107	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)	141
10.6.3	GCC COUNTRIES	141
11	COMPETITIVE LANDSCAPE	142
11.1	OVERVIEW	142
11.2	STRATEGIES ADOPTED BY KEY PLAYERS	142
11.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIAC MARKER TESTING MARKET	143
11.3	REVENUE SHARE ANALYSIS	144
FIGURE 27	REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET, 2018-2022 (USD MILLION)	144
11.4	MARKET RANKING ANALYSIS	145
11.5	COMPANY EVALUATION MATRIX	147
11.5.1	STARS	147
11.5.2	EMERGING LEADERS	147
11.5.3	PERVASIVE PLAYERS	147
11.5.4	PARTICIPANTS	147
FIGURE 29	CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX, 2022	148
11.6	STARTUP/SME EVALUATION MATRIX	149
11.6.1	PROGRESSIVE COMPANIES	149
11.6.2	STARTING BLOCKS	149
11.6.3	RESPONSIVE COMPANIES	149
11.6.4	DYNAMIC COMPANIES	149
FIGURE 30	CARDIAC MARKER TESTING MARKET: STARTUP/SME EVALUATION MATRIX, 2022	150
11.7	COMPANY FOOTPRINT	151
TABLE 108	PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET	151
TABLE 109	PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET	152
TABLE 110	REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET	153
11.8	COMPETITIVE SCENARIOS AND TRENDS	154
TABLE 111	KEY PRODUCT LAUNCHES	154
TABLE 112	KEY DEALS	155
TABLE 113	OTHER KEY DEVELOPMENTS	156
12	COMPANY PROFILES	157
12.1	KEY PLAYERS	157
	(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*	
12.1.1	F. HOFFMANN-LA ROCHE AG	157
TABLE 114	F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW	157
FIGURE 31	F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)	158
12.1.2	ABBOTT LABORATORIES	162
TABLE 115	ABBOTT LABORATORIES: COMPANY OVERVIEW	162
FIGURE 32	ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)	163
12.1.3	SIEMENS HEALTHINEERS AG	166

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 116 □SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW □166
FIGURE 33 □SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) □167
12.1.4 □DANAHER CORPORATION □170
TABLE 117 □DANAHER CORPORATION: COMPANY OVERVIEW □170
FIGURE 34 □DANAHER CORPORATION: COMPANY SNAPSHOT (2022) □171
12.1.5 □BIO-RAD LABORATORIES, INC. □173
TABLE 118 □BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW □173
FIGURE 35 □BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) □174
12.1.6 □BIOMERIEUX SA □176
TABLE 119 □BIOMERIEUX SA: COMPANY OVERVIEW □176
FIGURE 36 □BIOMERIEUX SA: COMPANY SNAPSHOT (2022) □177
12.1.7 □BECTON, DICKINSON AND COMPANY □178
TABLE 120 □BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW □178
FIGURE 37 □BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) □179
12.1.8 □THERMO FISHER SCIENTIFIC INC. □181
TABLE 121 □THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW □181
FIGURE 38 □THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) □182
12.1.9 □DIASORIN S.P.A. □184
TABLE 122 □DIASORIN S.P.A.: COMPANY OVERVIEW □184
FIGURE 39 □DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) □185
12.1.10 □PERKINELMER INC. □187
TABLE 123 □PERKINELMER INC.: COMPANY OVERVIEW □187
FIGURE 40 □PERKINELMER INC.: COMPANY SNAPSHOT (2022) □188
12.1.11 □TOSOH CORPORATION □190
TABLE 124 □TOSOH CORPORATION: COMPANY OVERVIEW □190
FIGURE 41 □TOSOH CORPORATION: COMPANY SNAPSHOT (2023) □191
12.1.12 □LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) □193
TABLE 125 □LSI MEDIENCE CORPORATION: COMPANY OVERVIEW □193
FIGURE 42 □PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) □194
12.1.13 □QUIDEL CORPORATION □195
TABLE 126 □QUIDEL CORPORATION: COMPANY OVERVIEW □195
FIGURE 43 □QUIDEL CORPORATION: COMPANY SNAPSHOT (2022) □196
12.1.14 □RANDOX LABORATORIES □198
TABLE 127 □RANDOX LABORATORIES: COMPANY OVERVIEW □198
12.1.15 □GUANGZHOU WONDFO BIOTECH CO., LTD. □200
TABLE 128 □GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW □200
12.1.16 □BODITECH MED INC. □202
TABLE 129 □BODITECH MED INC.: BUSINESS OVERVIEW □202
12.1.17 □TULIP DIAGNOSTICS (P) LTD. □204
TABLE 130 □TULIP DIAGNOSTICS (P) LTD.: BUSINESS OVERVIEW □204
12.1.18 □BTNX INC. □205
TABLE 131 □BTNX INC.: BUSINESS OVERVIEW □205
12.1.19 □RESPONSE BIOMEDICAL □207
TABLE 132 □RESPONSE BIOMEDICAL: BUSINESS OVERVIEW □207
12.1.20 □ALFA SCIENTIFIC DESIGNS, INC. □209
TABLE 133 □ALFA SCIENTIFIC DESIGNS, INC.: BUSINESS OVERVIEW □209
12.2 □OTHER PLAYERS □210

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.1 CTK BIOTECH, INC. 210
- 12.2.2 CREATIVE DIAGNOSTICS 211
- 12.2.3 LIFESIGN LLC 211
- 12.2.4 CARADIOGENICS HOLDINGS INC. 212
- 12.2.5 ATLAS MEDICAL GMBH 212

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

- 13 APPENDIX 213
 - 13.1 DISCUSSION GUIDE 213
 - 13.2 KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL 218
 - 13.3 CUSTOMIZATION OPTIONS 220
 - 13.4 RELATED REPORTS 220
 - 13.5 AUTHOR DETAILS 221

Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028

Market Report | 2023-10-25 | 216 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-17

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com